Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Sacubitril/valsartan - Novartis

Drug Profile

Sacubitril/valsartan - Novartis

Alternative Names: AHU-377/valsartan; dapagliflozin - Novartis; Enrest; Enresuto; Entresto; ENTRESTO SPRINKLE; LCZ-696; LCZ-696A; Neparvis; Valsartan/AHU-377; Valsartan/sacubitril

Latest Information Update: 17 Apr 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Novartis
  • Developer Novartis; Rovi
  • Class Antihypertensives; Biphenyl compounds; Branched-chain amino acids; Cardiovascular therapies; Erectile dysfunction therapies; Esters; Heart failure therapies; Pentanoic acids; Small molecules; Tetrazoles; Urologics
  • Mechanism of Action Angiotensin type 1 receptor antagonists; Neprilysin inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Marketed Essential hypertension; Heart failure; Hypertension
  • Phase III Erectile dysfunction; Kidney disorders
  • Phase II Hypertrophic cardiomyopathy

Most Recent Events

  • 12 Apr 2024 Registered for Heart failure (In adolescents, In children, In infants) in USA (PO)
  • 01 Feb 2024 Novartis plans a phase III trial for Hypertension (Treatment naïve, Monotherapy, Combination therapy) (PO, Tablet) (NCT06236061)
  • 29 Dec 2023 Novartis completes phase III trial in Heart failure (In infants, In children, In adolescents) in USA, Argentina, Austria, Bulgaria, Canada, Croatia, Czechia, Finland, France, Germany, Hungary, India, Israel, Italy, Japan, South Korea, Lebanon, Poland, Portugal, Russia, Singapore, South Africa, Spain, Switzerland, Taiwan, Thailand and Turkey (PO, Tablet, Capsule, Liquid) (NCT03785405)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top